Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma

Gynecologic Oncology

Volumn 92, Issue 2, 2004, Pages 635-638

  Tiersten, Amy D ^a   Selleck, Meredith J ^a   Hershman, Dawn L ^a   Smith, D ^a   Resnik, Edward E ^a   Troxel, Andrea B ^a   Brafman, Lois B ^a   Shriberg, Laureen ^a  

^a New York Presbyterian Hospital Columbia University Medical Center   (United States)

Author keywords

Cervical cancer; Combination therapy; Paclitaxel; Topotecan

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; TOPOTECAN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EVALUATION; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HUMAN TISSUE; LEUKOPENIA; METASTASIS; NAUSEA; NEUROTOXICITY; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SIDE EFFECT; STANDARDIZATION; THROMBOCYTOPENIA; TOXICITY; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA; VOMITING;

EID: 0842288949     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2003.11.019     Document Type: Article

References (15)

1. Jemal A., Murray T., Samuels A., Ghafoor A., Ward E., Thun M.J. Cancer statistics, 2003. CA Cancer J. Clin. 53:2003;5-26.
2. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Edwards BK (eds). SEER Cancer Statistics Review, 1973-1999. [National Cancer Institute Web site]. Bethesda, MD, 2002. Available at: http://seer.cancer.gov/csr/ 1973_1999/ ; 2001. Accessed February 17, 2003.
3. Thigpen T., Shingleton H., Homesley H., Lagasse L., Blessing J. Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Cancer. 48:1981;899-903.
4. Bonomi P., Blessing J.A., Stehman F.B., DiSaia P.J., Walton L., Major F.J. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a gynecologic oncology group study. J. Clin. Oncol. 3:1985;1079-1085.
5. Thigpen J.T., Blessing J.A., DiSaia P.J., Fowler W.C. Jr., Hatch K.D. A randomized comparison of a rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol. Oncol. 32:1989;198-202.
6. Curtin J.P., Blessing J.A., Webster K.D., Rose P.G., Mayer A.R., Fowler W.C. Jr.et al. Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a gynecologic oncology group study. J. Clin. Oncol. 19:2001;1275-1278.
7. Muderspach L.I., Blessing J.A., Levenback C., Moore J.L. Jr. A phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol. Oncol. 81:2001;213-215.
8. Bahadori H.R., Green M.R., Catapano C.V. Synergistic interaction between topotecan and microtubule-interfering agents. Cancer Chemother. Pharmacol. 48:2001;188-196.
9. O'Reilly S., Fleming G.F., Barker S.D., Walczak J.R., Bookman M.A., McGuire W.P. IIIet al. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a gynecologic oncology group study. J. Clin. Oncol. 15:1997;177-186.
10. Freifeld AG, Pizzo PA. The outpatient management of febrile neutropenia in cancer patients Oncology (Huntingt) 1996; 10: 599-606, 611-2; [discussion 615-6].
11. Papadimitriou C.A., Sarris K., Moulopoulos L.A., Fountzilas G., Anagnostopoulos A., Voulgaris Z.et al. Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix. J. Clin. Oncol. 17:1999;761-766.
12. Omura G.A., Blessing J., Vaccarello L., Berman M., Mutch D., Clarke-Pearson D.et al. A randomized trial of cisplatin (C) versus C + mitolactol (CM) versus C + ifosfamide (CIFX) in advanced squamous carcinoma of the cervix (SCC) by the Gynecologic Oncology Group (GOG). Proc. Am. Soc. Clin. Oncol. 14:1995;267. [abstract 736].
13. Moore D.H., McQuellon R.P., Blessing J.A., Thaler H., Benda J., Miller D.S.et al. A randomized phase III study of cisplatin versus cisplatin plus paclitaxel in Stage IVB, recurrent or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Proc. Am. Soc. Clin. Oncol. 20:2001;201a. [abstract 801].
14. Bookman M.A., Blessing J.A., Hanjani P., Herzog T.J., Andersen W.A. Topotecan in squamous cell carcinoma of the cervix: a phase II study of the gynecologic oncology group. Gynecol. Oncol. 77:2000;446-449.
15. McGuire W.P., Blessing J.A., Moore D., Lentz S.S., Photopulos G. Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. J. Clin. Oncol. 14:1996;792-795.